EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Xinchao Wu iD, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan iD

Advanced Science · 2026

DOI: 10.1002/advs.202521936 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Science, 2026. Verfasst von Xinchao Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Artificial Intelligence. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 210 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fred and Pamela Buffett Cancer Center, National Science Foundation, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer immunotherapy, which leverages the immune system to combat tumor cells, has made significant advancements in oncology treatment in recent years. Yet significant challenges remain in predicting treatment responses and understanding mechanisms of resistance. Artificial intelligence (AI) and machine learning (ML) provide powerful tools to address these challenges, enabling breakthroughs in patient stratification, biomarker discovery, and treatment strategy optimization. While remarkable progress has been made in developing deep learning frameworks, including large language models (LLMs) to integrate the exponentially growing multi‐omics biomedical data for cancer immunotherapy, little effort has been made to systematically and comprehensively summarize these developments or critically evaluate their translational potential. To fill these gaps, this review comprehensively examines the current landscape and future directions of AI/ML applications in cancer immunotherapy. Specifically, we discuss four key areas in AI for cancer immunotherapy: (1) patient stratification, (2) biomarker discovery, (3) treatment strategy optimization, and (4) foundation models and LLMs for cancer immunotherapy. In addition, we also critically discuss current limitations and future directions for existing AI approaches for cancer immunotherapy, highlighting the actionable insights and roadmaps to accelerate the integration of AI/ML into precision cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsArtificial IntelligenceHumansLarge Language ModelsMachine Learning

Stichwörter der Autor:innen

artificial intelligencecancer immunotherapyfoundation modelmachine learningmulti‐omics

Autor:innen und Institutionen

  • Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, USA.

ORCID-Profile: Xinchao Wu, Shibiao Wan

Förderung

  • Fred and Pamela Buffett Cancer Center
  • National Science Foundation
  • NIGMS NIH HHS
  • NIH Office of the Director
  • NIH HHS
  • NCI NIH HHS
  • American Cancer Society
  • Child Health Research Institute, University of Nebraska Medical Center

Zitieren

APA

Wu, X., Sun, M., Li, L., Wang, J., & Wan, S. (2026). Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202521936

Vancouver

Wu X, Sun M, Li L, Wang J, Wan S. Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy. Advanced Science. 2026. doi:10.1002/advs.202521936

BibTeX
@article{Wu2026,
  author = {Wu, Xinchao and Sun, Mengtao and Li, Lusheng and Wang, Jieqiong and Wan, Shibiao},
  title = {Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202521936}
}
Kostenlos starten →